2016. Efficacy, Durability, And Retreatment Outcomes Of Risankizumab In Moderate To Severe Plaque Psoriasis: Results From The Phase 3 Immhance Trial. Journal of Carcinogenesis. 15, 1 (Dec. 2016). DOI:https://doi.org/10.64149/.